(Q36400144)

14 August 2017

1 reference

title

Targeting of EGFR tyrosine kinase by ZD1839 ("Iressa") in androgen-responsive prostate cancer in vitro (English)

1 reference

14 August 2017

1 reference

Ilaria Bellezza

1

1 reference

14 August 2017

Sergio Bracarda

series ordinal

2

1 reference

14 August 2017

Claudia Caserta

series ordinal

3

1 reference

14 August 2017

Alba Minelli

series ordinal

4

1 reference

14 August 2017

publication date

17 February 2006

1 reference

Molecular Genetics and Metabolism

14 August 2017

published in

1 reference

14 August 2017

volume

88

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

114-122

1 reference

Untangling the ErbB signalling network

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Epidermal growth factor-related peptides and their receptors in human malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Can an autocrine loop explain sex-hormone-dependent tumor growth? A brief overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Epidermal growth factor receptor: mechanisms of activation and signalling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumour biopsies in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Epidermal growth factor receptor dependence in human tumors: more than just expression?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

The epidermal growth factor receptor and its inhibition in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

The EGF receptor system as a target for antitumor therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Signal transduction pathways: the molecular basis for targeted therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Expression of androgen receptor and growth factors in premalignant lesions of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

EGFR and cancer prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Screening for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Molecular genetics and epidemiology of prostate carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Endocrine Therapy for Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Treatment of advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Role of the androgen receptor axis in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Growth factors involved in prostate carcinogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Interleukin-6 regulation of prostate cancer cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Her-2-neu expression and progression toward androgen independence in human prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Insulin-like growth factors and neoplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

The IGF‐1 receptor in cancer biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Expression and function of androgen receptor coactivators in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

The discovery of receptor tyrosine kinases: targets for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Why the epidermal growth factor receptor? The rationale for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Tyrosine kinase inhibitors: a clinical perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

The Willet F. Whitmore, Jr., Lectureship: blockade of epidermal growth factor receptors as anticancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Review of epidermal growth factor receptor biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Growth factors and their receptors: new targets for prostate cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Synergistic antiproliferative and apoptotic effects induced by mixed epidermal growth factor receptor inhibitor ZD1839 and nitric oxide donor in human prostatic cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Increase in amphiregulin and epiregulin in prostate cancer xenograft after androgen deprivation-impact of specific HER1 inhibition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.12.014

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YMGME.2005.12.014

1 reference

14 August 2017

1 reference